NTEC - Intec Pharma Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.2803
+0.0013 (+0.47%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.2790
Open0.2708
Bid0.2350 x 1000
Ask0.0000 x 3200
Day's Range0.2708 - 0.2850
52 Week Range0.2300 - 9.2500
Volume730,100
Avg. Volume844,813
Market Cap10.294M
Beta (5Y Monthly)-0.06
PE Ratio (TTM)N/A
EPS (TTM)-1.6090
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.78
  • Top Marijuana Stocks on the NASDAQ
    Investopedia

    Top Marijuana Stocks on the NASDAQ

    The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.

  • GlobeNewswire

    Intec Pharma Announces Pricing of $6.5 Million Public Offering

    In addition, the Company granted the underwriter a 30-day option to purchase up to an additional 2,437,500 ordinary shares and/or warrants to purchase up to 2,437,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The Company expects to receive gross proceeds of $6.5 million from the offering.

  • PR Newswire

    Intec Pharma Announces Proposed Public Offering

    Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that it intends to offer and sell a combination of ordinary shares (or pre-funded warrants to purchase ordinary shares in lieu thereof) and warrants to purchase ordinary shares in an underwritten public offering. In addition, the Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of ordinary shares and/or warrants at the public offering price, less underwriting discounts and commissions. All of the ordinary shares and warrants in the offering will be sold by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

  • PR Newswire

    Intec Pharma Issues Letter to Shareholders

    Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today provides a business and clinical update on its development programs with the Company's proprietary oral drug delivery system, the Accordion Pill® platform, in a Letter to Shareholders. The full text of the letter is below.

  • Hedge Funds Aren’t Crazy About Intec Pharma Ltd (NTEC) Anymore
    Insider Monkey

    Hedge Funds Aren’t Crazy About Intec Pharma Ltd (NTEC) Anymore

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • PR Newswire

    Intec Pharma Provides Update on Novartis Feasibility and Option Agreement

    Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces the termination of the Feasibility and Option agreement with Novartis for the development of a custom-designed Accordion Pill® (AP) for a proprietary Novartis compound, despite the AP having met the technical and pharmacokinetic (PK) clinical specifications set forth by Novartis. Novartis, following an internal and revised commercial strategic assessment, advised Intec that this program no longer meets Novartis' mid to long-term strategic goals. Novartis agreed to pay Intec Pharma $1.5 million USD on conclusion of the program.

  • PR Newswire

    Intec Pharma to Present at LD Micro's 12th Annual Main Event

    Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will be participating in the 12th Annual LD Micro Main Event investor conference.

  • PR Newswire

    Intec Pharma Announces $10 Million Ordinary Shares Purchase Agreement With Aspire Capital

    Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company has entered into an Ordinary Shares Purchase Agreement for $10.0 million with Aspire Capital Fund, LLC ("Aspire Capital"), a Chicago-based institutional investor. Under the terms of the Agreement, Aspire Capital is committed to purchase up to $10.0 million of Intec Pharma's ordinary shares over a 30-month period extending into 2022, subject to certain terms and conditions. There are no warrants, derivatives, or other share classes associated with this agreement. Proceeds from the Agreement will be used to fund the Company's research and development activites, for working capital and for general corporate purposes.

  • PR Newswire

    Intec Pharma to Participate in Jefferies London Healthcare Conference

    JERUSALEM, Nov. 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that Company management will participate in the Jefferies London Healthcare Conference. Mr. Meckler's presentation will be webcast live and will be accessible through the Events section of Intec Pharma's website at www.intecpharma.com, where it will also be archived for a period of time.

  • PR Newswire

    Intec Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update

    JERUSALEM , Nov. 12, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three and nine months ended September ...

  • PR Newswire

    Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society

    JERUSALEM , Sept. 25, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters highlighting data from the Company's Phase 3 ...

  • PR Newswire

    Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society

    JERUSALEM , Sept. 16, 2019 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters in support of the Company's Phase 3 clinical ...

  • PR Newswire

    Intec Pharma to Participate in September Investment Conferences

    JERUSALEM, Sept. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming investment conferences in September.

  • Implied Volatility Surging for Intec Pharma (NTEC) Stock Options
    Zacks

    Implied Volatility Surging for Intec Pharma (NTEC) Stock Options

    Investors need to pay close attention to Intec Pharma (NTEC) stock based on the movements in the options market lately.

  • Can European Expansion Aid Canopy Growth (CGC) Q1 Earnings?
    Zacks

    Can European Expansion Aid Canopy Growth (CGC) Q1 Earnings?

    Canopy Growth's (CGC) recent acquisition of European companies will help it expand its production footprint into one of the most promising international regions.

  • PR Newswire

    Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update

    JERUSALEM , Aug. 9, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three and six months ended June 30 , 2019.   ...

  • ArQule (ARQL) to Post Q2 Earnings: What's in the Cards?
    Zacks

    ArQule (ARQL) to Post Q2 Earnings: What's in the Cards?

    On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.

  • Why Did Intec Pharma Crash on Monday?
    Market Realist

    Why Did Intec Pharma Crash on Monday?

    On Monday, Intec Pharma (NTEC) closed at $0.55—81.61% lower than the previous close. The company failed the pivotal Phase 3 ACCORDANCE trial.

  • Benzinga

    Intec Shares Slammed As Advanced Parkinson's Disease Drug Combo Flunks Late-Stage Study

    Intec, a clinical-stage biotech that develops drugs based on its proprietary Accordion Pill platform technology, said top-line data from a pivotal Phase 3 trial dubbed ACCORDANCE did not achieve the primary endpoint. The study evaluated the safety and efficacy of the Accordion Pill – Carbidopa/Levodopa compared with immediate release Carbidopa/Levodopa for treating symptoms of advanced Parkinson's disease, with a reduction in daily OFF time being the primary endpoint.

  • PR Newswire

    Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

    Conference Call to begin at 8:30 am ET JERUSALEM , July 22, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces top-line data from the Company's ...

  • CNW Group

    Horizons ETFs Rebalances Marijuana-Focused ETFs

    Horizons ETFs Rebalances Marijuana-Focused ETFs

  • PR Newswire

    Intec Pharma Announces Publication of Article Reviewing Accordion Pill's Unique Gastric Retention Platform in Therapeutic Delivery

    JERUSALEM, July 1, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announced that a review highlighting the benefits of the Accordion Pill® (AP) oral drug delivery platform was published in the peer-reviewed journal, Therapeutic Delivery.  The article titled, "The Accordion Pill®: unique oral delivery to enhance pharmacokinetics and therapeutic benefit of challenging drugs," highlights the technical and clinical achievements of the AP platform in a variety of applications. The article is now available online as an e-publication ahead of print and can be accessed here. The AP is an oral drug delivery system that uses biodegradable polymeric films, which combine and load drugs and inactive ingredients onto the films, folds the films into an undulated shape and then places them inside a capsule.

  • Here’s What Hedge Funds Think About Intec Pharma Ltd (NTEC)
    Insider Monkey

    Here’s What Hedge Funds Think About Intec Pharma Ltd (NTEC)

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • PR Newswire

    Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders

    Accordion Pill demonstrated more stable levodopa concentrations and significantly reduced OFF time in Parkinson's disease patients JERUSALEM , June 25, 2019 /PRNewswire/ ---  Intec Pharma Ltd. (NASDAQ: ...